Hyruan ONE® is the official global commercial brand name, and Yinikang is its Chinese brand name developed by LG Chem. It is a BDDE‑cross‑linked sodium hyaluronate preparation. By injecting into knee joint cavity, it supplements intra‑articular hyaluronic acid, improves joint lubrication, reduces friction, relieves joint pain and improves knee‑joint mobility.
Main Indications
Relief of pain symptoms associated with knee osteoarthritis in adult patients.
Clinical Research
Multicenter clinical trials demonstrated that BDDE‑crosslinked sodium hyaluronate effectively alleviates knee‑joint pain, improves joint function and physical activity ability for patients with knee osteoarthritis;
Clinical observation verified persistent pain‑relieving effect after intra‑articular injection treatment;
Domestic multi‑center clinical trials in Chinese patients confirmed good efficacy and local safety performance consistent with global clinical data.
Common Side Effects
Local injection‑site reactions: joint swelling, joint pain, injection‑site tenderness, erythema;
Rare but severe risks: intra‑articular infection, allergic reaction;
Common mild adverse reactions: local heat sensation, slight stiffness of knee joint.
Approval Status in China
Original drug Hyruan ONE® (BDDE‑Crosslinked Sodium Hyaluronate Injection) was officially approved for marketing in China in 2023, with the specification of 3 ml:60 mg. It is currently a prescription drug
Buy Hyruan ONE (BDDE‑Crosslinked Sodium Hyaluronate Injection) online from China and save up to 80% on costs . no insurance needed . compare prices from a certified HongKong pharmacy .with fast shipping. Contact us now on WhatsApp to get the latest prices.
